BPIQ Blog

Dec 9, 20193 min read

Merck acuires Arqule: Non-covalent Btk kinase inhibitors take center stage

Merck (MRK.N) reported today that it is buying ARQL for over a 100% premium from Friday's closing price (https://reut.rs/341eQv1). This...

Nov 14, 20194 min read

AMRN - Near-Term Price Acton Depends on Breadth of Label, but Acquisition Chatter and Quarterly Resu

Today, an advisory committee appointed by the FDA met and voted to recommend to the FDA that it expands the label for AMRN's...

Jul 2, 20194 min read

ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co

Central nervous system (CNS) disorder drug development is a particularly difficult branch of biopharma drug development. ITCI has...

Jun 25, 20192 min read

Lots of Uncertainty in Upcoming GLYC Sickle Cell Readout

GLYC has what is likely to be a binary event reading out later this year, likely in the next 45 days, with the phase 3 readout of its...

Jun 14, 20192 min read

ARQL 531 - Blood Cancer Promise and Fuel for ARQL Investors

Congrats to ARQL and especially CLL (a type of blood cancer) patients on the impressive early-stage data presented today at a poster...

May 29, 20192 min read

CARA Reports Success in Kidney Disease Itching

Congrats to CARA on a well-executed and positive Phase 3 trial of KORSUVA injection for reduction of pruritis (severe itching) in...

May 21, 20191 min read

ARRY shows encouraging Ph3 data in BRAF mutant CRC

Congrats to ARRY on positive data for mutant BRAF colorectal cancer (CRC). This interim data should lead to FDA/EMA approvals in this...

Apr 29, 20195 min read

FDA Decision on Heron's Non-Opioid Pain Med Imminent

We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011....

Apr 17, 20194 min read

Amp Core Q2 '19 Report

Q2 2019 Amp Core™ Quarterly Report Published 4/17/19 OVERVIEW We were looking for a rebound in small/mid ("smid") cap biopharma stocks in...

Apr 8, 20197 min read

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

(For a longer version of this article, with more detailed legal facts, please CLICK HERE.) Concert (CNCE) and Incyte (INCY) have been...

Apr 2, 20192 min read

SGMO Shows Early Progress in Gene Therapy and Ex-Vivo Programs

Sangamo (SGMO) provided an update today on its clinical programs, with its first clinical data for its Phase I Hemophilia A (gene...

Mar 28, 20192 min read

SUPN Reports Mixed Results in ADHD

SUPN reported mixed positive results today for its final phase 3 trial for SPN-812 in attention deficit hyperactivity disorder (ADHD).*...

Mar 26, 20191 min read

ALDX Presents Positive Ph3 Data in Allergic Conjunctivitis

Congrats to ALDX on strong Ph3 data in allergic conjunctivitis (AC) not only showing statistical significant area under curve for ocular...

Mar 18, 20192 min read

FDA Accepts AIMT's Peanut Allergy Treatment BLA For Review

AIMT is seeking approval for AR101 as a treatment to reduce the risk of anaphylaxis following accidental exposure to peanuts in children...

Mar 17, 20192 min read

Imminent Key Cystic Fibrosis Read-Outs for Proteostatis

Proteostasis (PTI) is scheduled to release data from 4 early-phase trials in Cystic Fibrosis (CF) imminently (i.e. this quarter) for all...

Mar 14, 20191 min read

UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success

Based on robust Ph2B and Ph3 (Japan) data in prior trials with similar design, it appears highly likely that UROV's Vibegron will meet...

Mar 12, 20191 min read

HRTX Opioid-Free Pain Med Candidate Continues to Impress

Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest...

Mar 8, 20193 min read

ARQL Surprises Investors with Clinical Trial Updates

ARQL pleasantly surprised investors yesterday on its quarterly call by giving two positive clinical trial updates. First, and most...

Mar 2, 20192 min read

Weekly Growth Hormone Phase 3 Results Imminent

We eagerly await Ascendis's (ASND) imminent phase 3 top-line results for its weekly growth hormone therapeutic candidate, TransCon GH....

Mar 1, 20192 min read

HZNP Reports Excellent Phase 3 Data for Thyroid Eye Disease

Congrats to Horizon Pharma (HZNP) and especially patients with thyroid eye disease (TED), on the positive phase 3 results reported...

Jump start your biotech due diligence

Get started →

Our platform helps you uncover your next biotech investment opportunity